Newsroom | 41671 results

AMSTERDAM--(BUSINESS WIRE)--Royal Philips (NYSE: PHG, AEX: PHIA), een wereldwijde marktleider op het gebied van gezondheidstechnologie, en Imricor Medical Systems (ASX: IMR), een pionier en toonaangevende ontwikkelaar van MR-compatibele producten voor interventionele MR-procedures, hebben vandaag een nieuwe laboratoriumoplossing voor interventionele MR (iMR) aangekondigd voor de 1,5T MR-scanners van Philips. Deze eerste commercieel beschikbare configuratie combineert het 1,5T MRI-platform van P...

ÁMSTERDAM--(BUSINESS WIRE)--Royal Philips (NYSE: PHG, AEX: PHIA), líder mundial en tecnología sanitaria, e Imricor Medical Systems (ASX: IMR), empresa pionera y líder mundial en el desarrollo de productos compatibles con RM para procedimientos intervencionistas guiados por RM, han anunciado hoy una nueva solución de RM intervencionista (iMR) para los equipos de RM de 1,5 T de Philips. La primera configuración disponible comercialmente combina la plataforma de RM de 1,5 T de Philips con la carte...

VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. Building on the trusted QIAsymphony platform, with more than 3,300 cumulative placements worldwide, QIAsymphony Connect helps clinical laboratories standardize extraction across diverse assay workflows. The platform delivers highly concentrated DNA and...

AMSTERDAM--(BUSINESS WIRE)--Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for ca...

VANCOUVER, British Columbia--(BUSINESS WIRE)--The Government of Canada today announced funding of up to $31.25 million through the Strategic Response Fund (SRF) toward Kardium’s investment in a $125 million project to expand its manufacturing capabilities in Vancouver, British Columbia. The announcement was made by the Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions. The investment will support a major expansion of Kardiu...

MIAMI & LEAWOOD, Kan.--(BUSINESS WIRE)--The American Medical Society for Sports Medicine (AMSSM) and OpenEvidence today announced a partnership that will focus on co-developing AI-powered educational resources on sports medicine for both patients and clinicians. This exclusive collaboration brings the expertise of AMSSM’s sports medicine physicians to OpenEvidence, the leading AI-powered clinical decision support platform, and will build on the AMSSM’s robust foundation of educational materials....

NASHUA, N.H.--(BUSINESS WIRE)--Vascular Technology, Incorporated (“VTI” or the “Company”), a medical device company specializing in the development, manufacturing and sale of surgical devices, today announced the appointment of David Pierce to its Board of Directors. Pierce brings more than three decades of experience leading innovation, transformation and sustainable growth across global medical device and healthcare technology markets. He currently serves on the boards of Neuraptive Therapeut...

BALTIMORE--(BUSINESS WIRE)--Protaryx Medical, an innovative medical device company developing differentiated access solutions for minimally invasive left-heart procedures, today announced the successful completion of the first U.S. commercial cases using its FDA-cleared Protaryx Transseptal Puncture Device. The procedures were performed at UC Davis Health in Sacramento, California, by interventional cardiologist Gagan D. Singh, M.D. The first two commercial cases were performed during left atri...

ROCHESTER, N.Y.--(BUSINESS WIRE)--Transcat to Participate in Jefferies, Lake Street and D.A. Davidson Investor Conferences in September...

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2026 third quarter results for the period ended June 30, 2026. Full financial statements and management’s discussion and analysis are available on the Company’s profile at www.sedarplus.ca. Brent Ashton, Covalon’s Chief Executive Officer, commented, “Covalon’s third quarter of fiscal 2026 delivered outstandi...